EFV400+3TC300+TDF300mg tab/PAC-30 No CTN

General description:
Efavirenz 400mg + Lamivudine 300mg + Tenofovir Disoproxil Fumarate 300mg, equivalent to 245mg Tenofovir Disoproxil 300mg, film coated tablets, bottle pack of 30 without outer carton.

Technical Specifications
Each film coated tablet contains Efavirenz 400mg, Lamivudine 300mg and Tenofovir Disoproxil Fumarate 300 mg, equivalent to 245 mg Tenofovir Disoproxil as fixed dose combination.

Therapeutic class
Efavirenz is a Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Lamivudine is Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Tenofovir is a Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

Dosage, Instructions for use:
For more details, please see WHO treatment guidelines www.who.int/hiv/pub/guidelines/en/index.html and WHO Essential Medicines Library www.who.int/emlib/ or your regional/national guidelines.

Details about paediatric dosage schemes can be found at http://www.who.int/hiv/topics/paediatric/en/index.html

WHO generic tool for assessing paediatric ARV dosing
http://www.who.int/hiv/paediatric/generictool/en/

Indications
Management of HIV-1 infection in children and adults in combination with at least two other antiretroviral drugs. By mouth (oral) PO.

Shelf life:
24 months

Storage conditions:
Do not store above 30°C.

Other available formulations
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.